Limitations, agreements, and source contact

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2022-02-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

CANN.InnovationsMedical@sarahcannon.com

organization

Sarah Cannon Development Innovations, LLC

phone

844-710-6157

title

Dr. Jesus Berdeja

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice